News
Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough
Cardio Diagnostics Wins “Clinical Diagnostics Solution of the Year” Award From BioTech Breakthrough Annual Awards Program Recognizes Innovation in the Global Life Sciences and Biotechnology Industry CHICAGO, October 27, 2021 – Cardio Diagnostics, Inc., a...
Cardio Diagnostics Jan 2021 Press Release
Cardio Diagnostics’ Epi+Gen CHD at-home sampling kit: Potential patients fill out a screening questionnaire that is reviewed by a board-certified clinician. If eligible for the test, a sampling kit is sent to their home. After the sample is collected, it is shipped...
Cardio Diagnostics receives a Phase I NIH SBIR
Cardio Diagnostics received $225K in National Institutes of Health (NIH) funding to further develop our integrated genetic-epigenetic coronary heart disease risk screening technology.
Cardio Diagnostics receives Biotech Innovation Showcase Award
Cardio Diagnostics won the Biotech Innovation Showcase Award and received a $5,000 grand prize at the annual IowaBio Partnering for Growth Conference.
Coronary Heart Disease Risk Prediction Paper Published
Cardio Diagnostics’ simple DNA test is better at identifying those at risk for coronary heart disease than standard approaches. This manuscript details the performance of our technology and highlights its ability to more sensitively (by >30%) identify those at risk...
Validation Partnership with Intermountain Healthcare
We are very excited to announce that Cardio Diagnostics has partnered with Intermountain Healthcare to independently validate our integrated genetic-epigenetic technology!